Literature DB >> 27935690

International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.

Alexandra S Whale1, Alison S Devonshire1, George Karlin-Neumann2, Jack Regan2, Leanne Javier2, Simon Cowen3, Ana Fernandez-Gonzalez1, Gerwyn M Jones1, Nicholas Redshaw1, Julia Beck4, Andreas W Berger5, Valérie Combaret6, Nina Dahl Kjersgaard7, Lisa Davis8, Frederic Fina9, Tim Forshew10, Rikke Fredslund Andersen11, Silvia Galbiati12, Álvaro González Hernández13, Charles A Haynes14, Filip Janku15, Roger Lacave16, Justin Lee17, Vilas Mistry18, Alexandra Pender19, Anne Pradines20, Charlotte Proudhon21, Lao H Saal22, Elliot Stieglitz23, Bryan Ulrich24, Carole A Foy1, Helen Parkes1, Svilen Tzonev2, Jim F Huggett1,25.   

Abstract

This study tested the claim that digital PCR (dPCR) can offer highly reproducible quantitative measurements in disparate laboratories. Twenty-one laboratories measured four blinded samples containing different quantities of a KRAS fragment encoding G12D, an important genetic marker for guiding therapy of certain cancers. This marker is challenging to quantify reproducibly using quantitative PCR (qPCR) or next generation sequencing (NGS) due to the presence of competing wild type sequences and the need for calibration. Using dPCR, 18 laboratories were able to quantify the G12D marker within 12% of each other in all samples. Three laboratories appeared to measure consistently outlying results; however, proper application of a follow-up analysis recommendation rectified their data. Our findings show that dPCR has demonstrable reproducibility across a large number of laboratories without calibration. This could enable the reproducible application of molecular stratification to guide therapy and, potentially, for molecular diagnostics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27935690     DOI: 10.1021/acs.analchem.6b03980

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  14 in total

1.  An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection.

Authors:  Chen-Yin Ou; Tam Vu; Jonathan T Grunwald; Michael Toledano; Jan Zimak; Melody Toosky; Byron Shen; Jason A Zell; Enrico Gratton; Timothy J Abram; Weian Zhao
Journal:  Lab Chip       Date:  2019-03-13       Impact factor: 6.799

2.  Detection and quantification of beef and pork materials in meat products by duplex droplet digital PCR.

Authors:  Yicun Cai; Yuping He; Rong Lv; Hongchao Chen; Qiang Wang; Liangwen Pan
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

3.  Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.

Authors:  C B Thomsen; T F Hansen; R F Andersen; J Lindebjerg; L H Jensen; A Jakobsen
Journal:  J Exp Clin Cancer Res       Date:  2018-03-12

4.  Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.

Authors:  Andrea Forschner; Stephanie Weißgraeber; Dirk Hadaschik; Martin Schulze; Maria Kopp; Sabine Kelkenberg; Tobias Sinnberg; Claus Garbe; Saskia Biskup; Florian Battke
Journal:  Onco Targets Ther       Date:  2020-06-04       Impact factor: 4.147

5.  Next Generation Sequencing: From Research Area to Clinical Practice.

Authors:  Chiara Di Resta; Maurizio Ferrari
Journal:  EJIFCC       Date:  2018-11-07

Review 6.  Critical assessment of digital PCR for the detection and quantification of genetically modified organisms.

Authors:  Tigst Demeke; David Dobnik
Journal:  Anal Bioanal Chem       Date:  2018-03-24       Impact factor: 4.142

7.  Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.

Authors:  Andrea Forschner; Florian Battke; Dirk Hadaschik; Martin Schulze; Stephanie Weißgraeber; Chung-Ting Han; Maria Kopp; Maximilian Frick; Bernhard Klumpp; Nicola Tietze; Teresa Amaral; Peter Martus; Tobias Sinnberg; Thomas Eigentler; Ulrike Keim; Claus Garbe; Dennis Döcker; Saskia Biskup
Journal:  J Immunother Cancer       Date:  2019-07-12       Impact factor: 13.751

8.  Response: Concerns with conclusions in the article by Sherwood et al 'Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice'.

Authors:  James Sherwood
Journal:  ESMO Open       Date:  2018-01-03

9.  Concerns with conclusions in the article by Sherwood et al 'Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice'.

Authors:  George Karlin-Neumann
Journal:  ESMO Open       Date:  2018-01-03

10.  Evaluation of cross-platform and interlaboratory concordance via consensus modelling of genomic measurements.

Authors:  Timothy J Peters; Hugh J French; Stephen T Bradford; Ruth Pidsley; Clare Stirzaker; Hilal Varinli; Shalima Nair; Wenjia Qu; Jenny Song; Katherine A Giles; Aaron L Statham; Helen Speirs; Terence P Speed; Susan J Clark
Journal:  Bioinformatics       Date:  2019-02-15       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.